CRL Revenue
Revenue at Charles River Laboratories fell to $4.0B in fiscal 2025, from $4.0B in 2024.
Total revenues as filed (us-gaap fallback chain; for financials, net revenue or net interest income). Source tag recorded per name.
SOURCE: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · EDGAR CompanyFacts · CIK 1100682 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $4.0B | $-35M |
| FY2024 | $4.0B | $-79M |
| FY2023 | $4.1B | +$153M |
| FY2022 | $4.0B | +$436M |
| FY2021 | $3.5B | — |
More SAME DATA, OTHER VIEWS
Revenue across coverage → · CRL company view →
Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.